Blog
Drug Target Encyclopedia Series (13) — CD79
Release Time：
2025-12-05 13:48
CD79 (CD79A/CD79B) is a key component of the B cell receptor (BCR) complex, essential for B cell development, activation, and signal transduction. Aberrant CD79 signaling is closely linked to autoimmune diseases and B cell malignancies, making it an important therapeutic target.
CD79 is implicated in:
• B cell acute lymphoblastic leukemia (B-ALL)
• Diffuse large B-cell lymphoma (DLBCL)
• Chronic lymphocytic leukemia (CLL)
• Autoimmune disorders such as systemic lupus erythematosus (SLE)
Targeting CD79 in therapy:
- Monoclonal antibodies – Anti-CD79 antibodies can suppress B cell activation and survival.
- Antibody-drug conjugates (ADCs) – Polatuzumab vedotin (anti-CD79b ADC, FDA-approved) has shown strong efficacy in relapsed/refractory DLBCL.
- Bispecific antibodies – CD79b/CD3 bispecifics are under investigation to redirect T cells toward malignant B cells.
- CAR-T therapy – CD79-targeted CAR-T cells are in preclinical and clinical development, representing a novel strategy for B cell cancers.
Challenges include: balancing efficacy with immunosuppression, managing resistance in relapsed lymphomas, and minimizing off-target toxicity due to CD79 expression on normal B cells.
🔬 Ongoing research is exploring next-generation ADC payloads, combination regimens with checkpoint inhibitors, and engineered cell therapies to optimize the therapeutic index of CD79-targeted approaches.
Need CD79 tools for your research?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898